Eli Lilly Plans to Position India as a Global Supply Chain Hub as Demand for Mounjaro Grows 

Key Highlights:  

• Eli Lilly is looking to turn India into a hub for its global pharmaceutical supply chain, building on its previously committed $1 billion investment in contract manufacturing partnerships in the country. 

• The move comes as demand surges for Lilly’s obesity treatment Mounjaro, which quickly became the company’s top-selling product in India by value after launch, reflecting growing interest in weight-management therapies. 

• Alongside expanding manufacturing partnerships, Lilly plans to introduce additional therapies in India, including the Alzheimer’s drug Donanemab and experimental oral obesity drug Orforglipron, while strengthening distribution through partners such as Cipla and digital health platforms like Tata 1mg and Practo.  

Implications: 

Lilly’s India manufacturing bet locks in low-cost production muscle, outflanking China-dependent rivals as Mounjaro mania drives capacity race. 
Cipla/1mg partnerships blanket urban markets while Donanemab preps neuro assault, crushing smaller players in premium therapy distribution. 

Source: Reuters | Image: Eli Lilly